title: High-sensitivity C-reactive protein and mobility disability in older adults.
abstract: OBJECTIVE
  to determine the association of high sensitivity C-reactive protein (HsCRP) levels with a risk of mobility disability and decline in older adults with and without vascular disease.
  
  
  METHODS
  prospective cohort.
  
  
  METHODS
  community-residing population.
  
  
  METHODS
  six hundred and twenty-four adults age 70 and older (62% women) with gait and HsCRP assessments.
  
  
  METHODS
  incident mobility disability (velocity <70 cm/s) and annual rates of decline on gait velocity.
  
  
  RESULTS
  elevated HsCRP levels (≥ 3 mg/l) at baseline present in 224 of the 624 eligible subjects was associated with a faster annual decline in gait velocity of 0.91 cm/s (P=0.02). Subjects with elevated HsCRP levels had increased risk of mobility disability (hazard ratio: 1.85, 95% CI: 1.09-3.14). Each one-unit increase in log HsCRP levels in the 406 subjects without prevalent mobility disability was associated with increased risk of mobility disability (hazard ratio: 1.33, 95% CI: 1.05-1.68). The association of baseline HsCRP levels with mobility disability and decline was stronger in the 224 individuals without vascular disease. The associations were not significant in the 400 subjects with vascular disease.
  
  
  CONCLUSIONS
  HsCRP levels predict mobility disability and accelerated decline in walking speed in older adults. These associations were stronger in those without vascular disease.
authors.affiliation: Neurology, Albert Einstein College of Medicine, 1165 Morris Park Avenue, Einstein Aging Study, Bronx, NY 10461, USA. jverghes@aecom.yu.edu
authors.forename: Joe
authors.initials: J
authors.lastname: Verghese
authors.forename: Roee
authors.initials: R
authors.lastname: Holtzer
authors.forename: Richard B
authors.initials: RB
authors.lastname: Lipton
authors.forename: Cuiling
authors.initials: C
authors.lastname: Wang
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000097:blood / Q000276:immunology*; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis*; D004185:Disability Evaluation; D005260:Female; D005684:Gait; D015577:Geriatric Assessment; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood*; D016014:Linear Models; D008297:Male; D051346:Mobility Limitation; D009518:New York; D016016:Proportional Hazards Models; D011446:Prospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D015854:Up-Regulation
chemical_list: D015415:Biomarkers; D018836:Inflammation Mediators; D002097:C-Reactive Protein